Table 2.
Distribution of CDKN2A, IDH, ATRX, TP53 and 1p19q status by pathologic diagnosis in tumors from glioma patients in the UCSF Adult Glioma Study
| All cases | Diffuse astrocytoma (A-II) |
Anaplastic astrocytoma (A-III) |
Oligodendroglioma (O-II) |
Anaplastic oligodendroglioma (O-III) |
Oligoastrocytoma (OA-II) |
Anaplastic oligoastrocytoma (OA-III) |
||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| N | Percent | N | Percent | N | Percent | N | Percent | N | Percent | N | Percent | N | Percent | |
| CDKN2A | ||||||||||||||
| Intact | 159 | 63% | 26 | 55% | 30 | 49% | 57 | 77% | 16 | 73% | 25 | 63% | 5 | 56% |
| Deleted | 94 | 37% | 21 | 45% | 31 | 51% | 17 | 23% | 6 | 27% | 15 | 38% | 4 | 44% |
| Total | 253 | 47 | 61 | 74 | 22 | 40 | 9 | |||||||
| IDH | ||||||||||||||
| Wild type | 65 | 24% | 10 | 21% | 26 | 41% | 9 | 11% | 8 | 33% | 8 | 19% | 4 | 36% |
| Mutated | 202 | 76% | 37 | 79% | 37 | 59% | 71 | 89% | 16 | 67% | 34 | 81% | 7 | 64% |
| Total | 267 | 47 | 63 | 80 | 24 | 42 | 11 | |||||||
| ATRX | ||||||||||||||
| Intact | 156 | 60% | 22 | 47% | 24 | 39% | 68 | 86% | 20 | 87% | 18 | 44% | 4 | 36% |
| Lost | 106 | 40% | 25 | 53% | 37 | 61% | 11 | 14% | 3 | 13% | 23 | 56% | 7 | 64% |
| Total | 262 | 47 | 61 | 79 | 23 | 41 | 11 | |||||||
| TP53 | ||||||||||||||
| Wild type | 107 | 63% | 9 | 31% | 24 | 48% | 42 | 89% | 14 | 82% | 13 | 65% | 5 | 63% |
| Mutated | 64 | 37% | 20 | 69% | 26 | 52% | 5 | 11% | 3 | 18% | 7 | 35% | 3 | 38% |
| Total | 171 | 29 | 50 | 47 | 17 | 20 | 8 | |||||||
| 1p19q | ||||||||||||||
| Intact | 65 | 42% | NA* | NA* | 19 | 25% | 5 | 23% | 29 | 74% | 8 | 89% | ||
| Codeleted | 89 | 58% | 58 | 75% | 17 | 77% | 10 | 26% | 1 | 11% | ||||
| Total | 154 | 77 | 22 | 39 | 9 | |||||||||
*
NA, 1p19q data not available for tumors classified histologically as astrocytoma.